Exagen (XGN) Q1 2026 earnings review
Record Top-Line, But Profitability Remains Elusive
Exagen delivered a record $17.3M in revenue, up 12% YoY, breaking a slight sequential dip seen in late 2025. The core growth engines are firing: AVISE CTD test volume rose 10%, and the Trailing Twelve Month (TTM) Average Selling Price (ASP) expanded to $444. However, the volume recovery did not cascade to the bottom line as expected. Gross margins are Stable at a stubborn 59.0%, and the company remains unprofitable with a $2.2M Adjusted EBITDA loss. Management's strategic decision to hold insurance claims in Q1 drained cash by over $10M sequentially, testing investor patience on the long-promised pivot to cash flow positivity.
🐂 Bull Case
The strategy to simultaneously grow test volumes (+10%) and pricing power (ASP up $25 YoY) is working. Record revenue of $17.3M proves the commercial team is effectively capturing market share.
Adjusted EBITDA loss improved 14% YoY to $2.2M, signaling that the company is effectively managing operating expenses even as test volumes hit record highs.
🐻 Bear Case
Gross margin was 59.0%, virtually flat YoY (58.9%). The company desperately needs to cross the 60% threshold to achieve its profitability targets, but costs are scaling with revenue.
Management previously targeted a $90 ASP lift from new biomarkers. While TTM ASP rose to $444, the sequential growth is Decelerating (up only $3 from Q4 2025), indicating payer resistance is a real barrier.
⚖️ Verdict: ⚪
Neutral. Top-line execution is flawless and commercial demand is evident. However, the lack of gross margin expansion and the optical hit to cash balances keep the risk profile elevated until free cash flow turns structurally positive.
Key Themes
Cash Burn Contradicts "Effective Revenue Cycle" Narrative
Management praised their "effective revenue cycle management" in the press release, but the balance sheet tells a Reversing story. Cash and equivalents plummeted from $32.2M at the end of 2025 to $21.5M in Q1 2026. Simultaneously, Accounts Receivable spiked from $10.9M to $15.8M. While this is attributed to a "long-standing strategy to hold claims in the first quarter" to maximize reimbursement rates, it creates severe optical cash burn and leaves the company vulnerable if collection rates on these aged claims deteriorate.
AVISE CTD Test Volume Market Penetration
Test volume is Accelerating again. After a seasonally weaker Q4, Q1 2026 delivered 10% YoY volume growth. The sales force's productivity is evidently stable, proving that the demand for autoimmune diagnostic clarity remains a reliable top-line driver.
Gradual ASP Expansion
The Trailing Twelve Month Average Selling Price reached $444, up $25 (6%) YoY. While the pace is Decelerating compared to early 2025 expectations, this steady price realization is the primary driver for eventual gross margin expansion.
Clinical Utility via Biomarker Innovation
The foundation of Exagen's volume growth is specific technological innovation. The historical integration of novel T-Cell and seronegative Rheumatoid Arthritis (RA) biomarkers—specifically anti-PAD4 and anti-RA33—onto the AVISE CTD platform has armed the sales force with superior clinical data, capturing patients that traditional tests miss.
Gross Margin Stagnation
Gross margin came in at 59.0%, a metric that is entirely Stable YoY (58.9% in 25Q1). In previous quarters, management targeted mid-60s margins as a requisite for profitability. The failure to expand margins despite a $25 higher ASP implies that Cost of Goods Sold per test is rising proportionally, offsetting pricing wins.
Macro: Payer Reimbursement Friction
The broader macroeconomic environment for advanced diagnostics remains hostile. The gap between Exagen's list price and its $444 realized ASP is driven by systemic payer denials and medical policy hurdles—standard macro industry tactics to curtail utilization that require heavy, ongoing administrative investment to fight.
Operating Expense Discipline
Total operating expenses rose 9% YoY to $13.6M, which trailed the 12% revenue growth. This demonstrates modest operating leverage, a necessary step toward the long-delayed goal of positive cash flow.
Other KPIs
Improving. A 14% reduction in loss compared to Q1 2025's $(2.51) million. The company is slowly inching toward breakeven, but the path has been rocky and slower than the Q4 2025 profitability targets discussed in earlier quarters.
Stable. The GAAP operating loss barely budged from $(3.37) million a year ago. Revenue gains of $1.8M were almost entirely consumed by a $0.7M increase in Cost of Revenue and a $1.1M increase in Operating Expenses.
Guidance
Decelerating. The company reiterated its full-year guidance. At the $71.5M midpoint, this implies a 7.4% YoY growth rate over FY25's $66.6M. This is a sharp deceleration from the 20% YoY revenue growth achieved in FY25.
Key Questions
Collection Risk on Held Claims
You attributed the $10.7M drop in cash to holding Q1 claims. What is the historical realization rate on these specific bulk-released claims, and are there any risks of elevated denials due to timely filing limits?
Gross Margin Ceiling
With ASP up $25 year-over-year, gross margins remained flat at 59%. What specific COGS inflation is offsetting your pricing wins, and what is the new timeline to cross the 60% threshold?
Pharma Services Update
In Q3 2025, you highlighted a rapidly emerging Pharma and CRO services business with a $3.5 million backlog. There was no mention of this in the Q1 2026 release. Has this revenue stream materialized, or has it stalled?